Notice of Withdrawal of New External Director Nomination

Tokyo, Japan and London, UK, 4 June 2018 – Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announces that at the Nomination Committee meeting held on 4 June 2018, the Company determined to withdraw the nomination of Dr Michael Hayden as a new External Director. The appointment was scheduled to be voted on for approval at the 28th Ordinary General Meeting of Shareholders on 22 June 2018. The Board of Directors determined at its meeting held on 4 June 2018 to amend the proposal as stated below.

1. Background of the Withdrawal

- The Company and Dr Michael Hayden mutually agreed to withdraw his nomination as a new External Director.
- The Nomination Committee has determined that it will not nominate a replacement new External Director for election at the 28th Ordinary General Meeting of Shareholders.

2. Content of the Changes

- With regard to Proposal No. 2, the Election of 7 Directors is now changed to the Election of 6 Directors. The proposed amendments are summarized as follows.

(The underlined portions show the changes)

<table>
<tr><th colspan="2">Before change</th><th colspan="2">After change</th></tr>
<tr><td colspan="2">Proposal No. 2 Election of <u>Seven (7)</u> Directors

The terms of office of all five directors will expire upon conclusion of the Meeting. To enhance the supervisory function of the Board of Directors, the Company will have <u>two</u> more external Directors. Accordingly, the election of <u>seven</u> Directors including <u>three</u> new Directors shall be proposed. The proposal is presented based on a decision by the Nomination Committee.

The candidates are as shown below.</td><td colspan="2">Proposal No. 2 Election of <u>Six (6)</u> Directors

The terms of office of all five directors will expire upon conclusion of the Meeting. To enhance the supervisory function of the Board of Directors, the Company will have <u>one</u> more external Directors. Accordingly, the election of <u>six</u> Directors including <u>two</u> new Directors shall be proposed. The proposal is presented based on a decision by the Nomination Committee.

The candidates are as shown below.</td></tr>
<tr><td>Candidate No.</td><td>Name</td><td>Candidate No.</td><td>Name</td></tr>
<tr><td>1</td><td>Shinichi Tamura</td><td>1</td><td>Shinichi Tamura</td></tr>
<tr><td>2</td><td>Peter Bains</td><td>2</td><td>Peter Bains</td></tr>
<tr><td>3</td><td>Tomohiro Tohyama</td><td>3</td><td>Tomohiro Tohyama</td></tr>
<tr><td>4</td><td>Julia Gregory</td><td>4</td><td>Julia Gregory</td></tr>
<tr><td><u>5</u></td><td><u>Michael Hayden</u></td><td><u>5</u></td><td><u>Deleted</u></td></tr>
<tr><td>6</td><td>Kuniaki Kaga</td><td>6</td><td>Kuniaki Kaga</td></tr>
<tr><td>7</td><td>David Roblin</td><td>7</td><td>David Roblin</td></tr>
</table>

Note: Career summary, significant concurrent posts, etc. of each candidate are as described in the Reference Documents (Proposal) of the Notice of the 28th Ordinary General Meeting of Shareholders.

3. Exercise of voting rights by Voting Exercise Cards

- With regard to Proposal No.2 in (2) above, the exercise of voting rights by Voting Exercise Cards is treated as effective only for the six candidates after the change.

-Ends-

Enquiries:

Sosei Group +44 (0) 7912 892 199
Chris Cargill, Head of Investor Relations and Corporate Communications
ccargill@sosei.com

Citigate Dewe Rogerson (for international media) +44 (0) 20 7638 9571
Mark Swallow
David Dible
sosei@citigatedewerogerson.com

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit http://www.sosei.com/en/.